Main Industry
Health Care
Main Product/Service
continues to develop diverse oral medical solutions and has gained an excellent reputation in the industry. In the future, we will continue to increase our competitiveness and strive to become the most professional oral liquid pharmaceutical company, a leader in CNS field and an expert in special drug development and the biotech industry bank.
Founded Year
2013
Unified Business No.
54360142
Status
Active
Number of Employees
0
Total Paid-in
Capital
231,534,840 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Established in 1959, the Center Laboratories, Inc. (hereafter refers as the Company) founded as a pharmaceutical company specializing in full-dosage drugs development and manufacturing. In 1998, the company experienced its first reformed and repositioned itself as a professional oral liquid pharmaceutical company specializing in diverse liquid drugs development and manufacturing and offering wide range of liquid drug solutions for medication purpose. Thereafter, the Company achieved a remarkable market share of 70% within the domestic oral liquid drugs market in ten years horizon. Nevertheless, the vast majority of the market share also implying limited upside for the new sales growth. The Center Laboratories began its second business restructured and transformation with new innovations. In 2008, the Company reformed its business structure and shifted it business strategies focuses on dual growth engines emphasis on strategic and organic growths, while continue to expand its oral liquid drugs businesses. Post the business restructuring, the Center Laboratories began its second reformed and repositioned itself as “Biotechnology Industrial Bank” with initial investments made in the biotechnology industry through two of its major subsidiaries, the Bioengine capital inc., and the Bioengine Technology Development Inc. During the second reformed, the Company shifted its focuses on biotechnology investments and incubation. In 2018, the Center Laboratories again proven track record of delivering in both oral liquid drugs and biotechnology investments post second reformed. The first two reformation has resulted in great success for the Company while investments businesses continued to expand over years. In order to create synergies, the Company began to integrate its resources with another business transformations. The Center Laboratories initiated the third reformed and evolved into “Professional Biotechnology Venture Holdings Group,” (also renamed as the “Center Ventures Group”) that aiming to assist its target investment companies with the intention of revamping target investment company’s operations, with consolidation through Merger and Acquisition or re-selling at a profit. Overtimes, the Center Ventures Group has become one of the leading professional biotechnology incubator platforms in Asia Pacific. The Group targets to incubate more unicorn like companies with market cap exceeding NTD$ 30 billion each, while continue to seek for any potential opportunities in emergent industries that can serve as the second growth engines within the group.
